Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Opoku Frimpong has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A narrative review of lessons from Ghana’s COVID-19 response to inform future pandemic preparedness

    by Richard Owusu Ansah, Enoch M. Opey, Stephen Twumasi, Bridget B. Appiah, Emmanuel Owusu, Derrick K. Boakye, Richard Larbi, Raymond X. Sevor, James O. Frimpong, Gifty Nkrumah, et al.


  • Open Access

    Epidemiology and genotypic profiling of hepatitis B virus among febrile individuals in a high-endemic Ghanaian setting

    by James Opoku Frimpong, Ahmed Alhassan, Richard Owusu Ansah, Richard Larbi, Philip El-Duah, Dorcas Ohui Owusu, Thirumalaisamy P. Velavan, Michael Owusu

    Hepatitis B virus (HBV) remains a major public health concern in sub-Saharan Africa, where it is highly endemic and contributes substantially to liver-rela

  • Open Access

    Evaluating the diagnostic performance of miLab™ for detection of malaria parasites using nPCR as reference standard

    by Ebenezer Kojo Addae, Theophilus Awortwe-Quaicoe, Benedict Sackey, Richard Owusu Ansah, Richard Larbi, Kinako Denis Elia Dazangapai, James Opoku Frimpong, Thelma Owusuaa Ofori Amoako, Alexander Asamoah, Nana Ayisi-Boateng, et al.

    Malaria remains a leading health threat in sub-Saharan Africa, causing over 600,000 deaths annually. Ghana, ranked among the top 15 in malaria burden in Africa, relies heavily on microscopy for diagnosis due to its affordability and established use. However, limitations in sensitivity, turnaround time, and availability of skilled personnel despite ongoing national training efforts stress the need for improved diagnostics. This study evaluated miLab ™ , an AI-assisted automated malaria detection platform, using nested PCR (nPCR) as the reference standard. We conducted a hospital-based cross-sectional study from August 2024 to June 2025 in three malaria-endemic communities in Kumasi, Ashanti region and enrolled 300 suspected malaria patients (168 females, 132 males; aged 1–87 years, median 24). Blood samples were analyzed independently by miLab ™ , two independent mid-level microscopists, and nPCR. Discrepancies between the two microscopists were resolved by a WHO expert microscopist (adjudicated microscopy) to establish a microscopy reference standard. Diagnostic accuracy, correlation and measurement agreement were determined using GraphPad Prism Version 8. Parasite densities estimated by miLab ™ ranged from 0.95 to 5.34 log parasites/µL (median 3.52, IQR 2.93–3.91). For mid-level microscopist 1, densities ranged from 2.02 to 5.43, (median 4.02, IQR: 3.22–4.50), while Mid-level microscopist 2 measured densities between 1.98 and 5.22, (median 3.78, IQR: 3.15–4.23). When compared to nPCR, miLab ™ demonstrated a sensitivity of 94.23%, specificity of 98.98%, and accuracy of 97.33%, while adjudicated microscopy showed a sensitivity of 85.58%, specificity of 97.96%, and accuracy of 93.67%. These findings indicate that miLab ™ has better performance compared to microscopy for detection of malaria parasites. miLab™ could offer a reliable, rapid diagnostic alternative suitable for malaria-endemic, resource-limited settings where timely and accurate diagnosis is critical for effective case management and control.

  • Open Access

    Knowledge, attitudes and practices of antibiotic use among students in a Ghanaian tertiary institution

    by Kinako Denis Elia Dazangapai, Eric Darko, Richard Owusu Ansah, Barikisu Ekua Seidu Dawuda, Beatrice Nyantakyiwaa, Richard Larbi, James Opoku Frimpong, Raymond Xornam Sevor


  • Open Access

    Prevalence of Common Respiratory Viruses in Children: Insights from Post-Pandemic Surveillance

    by Constance Adu-Gyamfi, Jesse Addo Asamoah, James Opoku Frimpong, Richard Larbi, Richard Owusu Ansah, Sherihane Naa Ayeley Aryeetey, Richmond Gorman, Henry Kyeremateng Acheampong, Emmanuella Nyarko-Afriyie, Manuella Hayford, et al.

    Introduction: The COVID-19 pandemic has significantly affected healthcare systems worldwide, impacting the occurrence and management of respiratory illnesses. This has also influenced respiratory infections’ role in childhood mortality. Surveillance of common respiratory viruses in Ghana is limited, making it crucial to assess the prevalence of respiratory viral infections, particularly in children, in the post-pandemic era. This study provides data on the prevalence of respiratory viruses and the associated risk factors in children aged 5 or younger in an urban paediatric hospital setting. Methods: The study was a cross-sectional study with a convenience sampling method, conducted in four health facilities: Asokwa Children’s Hospital, HopeXchange Medical Centre, University Health Services-KNUST, and Kumasi South Hospital in Kumasi, Ghana, between August 2022 and June 2023. Recruitment was not done in parallel in each hospital. Oropharyngeal swabs were collected from children ≤ 5 years old and screened by RT-qPCR for common respiratory viruses. Results: Out of the 303 patients enrolled in the study, 165 (54.4%) were male, and 122 (40.3%) were aged from 13 to 36 months. The median age of the patients was 19 months. The most common symptoms reported were cough (87.0%), runny nose (87.0%), and fever (72.0%). Respiratory viruses were detected in 100 (33.0%) of the samples, with 36 (12.0%) testing positive for Human metapneumovirus (HMPV), 27 (8.9%) for RSV, and 20 (6.6%) for Human Adenovirus (HAdV). In 8.0% of the cases, multiple viruses were detected, with HAdV being the most common (75.0%). Children under 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had a higher risk of RSV detection compared to children aged 37 to 60 months. Furthermore, it was found that caregivers with tertiary education had a higher risk of HMPV detection (AOR: 6.91, 95% CI: 1.71-47.3). Conclusion: The study’s findings emphasize RSV infection in very young children and the potentially significant role of HMPV in causing respiratory infections among children in Ghana. Active surveillance of common respiratory viruses in healthcare facilities could enhance the management of viral respiratory infection cases in the paediatric population in Ghana.


  • Open Access

    Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population

    by Adam Abdullahi, James Frimpong, Mark T. K. Cheng, Sani H. Aliyu, Colette Smith, Alash’lE Abimiku, Richard Odame Phillips, Michael Owusu, Ravindra K. Gupta

    : Determination of previous SARS-COV-2 infection is hampered by the absence of a standardized test. The marker used to assess previous exposure is IgG antibody to the nucleocapsid (IgG anti-N), although it is known to wane quickly from peripheral blood. The accuracies of seven antibody tests (virus neutralization test, IgG anti-N, IgG anti-spike [anti-S], IgG anti–receptor binding domain [anti-RBD], IgG anti-N + anti-RBD, IgG anti-N + anti-S, and IgG anti-S + anti-RBD), either singly or in combination, were evaluated on 502 cryopreserved serum samples collected before the COVID-19 vaccination rollout in Kumasi, Ghana. The accuracy of each index test was measured using a composite reference standard based on a combination of neutralization test and IgG anti-N antibody tests. According to the composite reference, 262 participants were previously exposed; the most sensitive test was the virus neutralization test, with 95.4% sensitivity (95% CI: 93.6–97.3), followed by 79.0% for IgG anti-N + anti-S (95% CI: 76.3–83.3). The most specific tests were virus neutralization and IgG anti-N, both with 100% specificity. Viral neutralization and IgG anti-N + anti-S were the overall most accurate tests, with specificity/sensitivity of 100/95.2% and 79.0/92.1%, respectively. Our findings indicate that IgG anti-N alone is an inadequate marker of prior exposure to SARS COV-2 in this population. Virus neutralization assay appears to be the most accurate assay in discerning prior infection. A combination of IgG anti-N and IgG anti-S is also accurate and suited for assessment of SARS COV-2 exposure in low-resource settings.


  • Open Access

    SARS-CoV-2 Antibody Responses to AZD1222 Vaccination in West Africa

    by Adam Abdullahi, David Oladele, Michael Owusu, Steven Kemp, James Ayorinde, Abideen Salako, Douglas Fink, Augustina Sylverken, Fehintola Ige, Chika Onwuamah, et al.

    There is a paucity of real-world data on vaccine elicited neutralising antibody responses for AZD1222, in African populations following vaccination scale up. Here, we first measured baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using both flow cytometric based analysis of binding antibodies coupled with pseudotyped virus neutralisation assays in two study cohorts from West Africa: Nigerian healthcare workers; (n = 140) and a Ghanaian general community cohort (n = 527). We found that 44% and 28% of pre-vaccination participants showed IgG anti-N positivity, increasing to 59% and 42% respectively with anti-receptor binding dominan (RBD) IgG specific antibodies. The increased prevalence of prior exposure using anti RBD antibodies was corroborated by Pseudotyped virus (PV) neutralizing antibody assays, indicating that overall, 50% of prior infections were missed by N antibody testing. PV titres (serum dilution required to inhibit 50% of infection, ID50) against wild type following 2-dose vaccination regimen were [145 (4.5) to 2579 (4.2) vs 57 (3.0) to 1049 (6.7)] (GMT ± s.d), delta [75 (3.0) to 549 (3.7) vs 37 (2.4) to 453 (7.4)] (GMT ± s.d) and omicron variants [37 (2.4) to 453 (7.4) vs 29 (1.8) to 95 (5.3)] (GMT ± s.d) in the Nigerian (1 month) vs Ghanaian participants (2 months) post vaccination (total n = 94). Previous IgG anti-N was associated with significantly higher neutralizing antibody levels with an observed 3.5-fold [1423 (3.9) vs 4674 (3.4)] (GMT ± s.d) and 2.7-fold [779 (7.1) vs 2128 (4.8) (GMT ± s.d) difference between N positive and negative participants in the Nigerian and Ghanaian cohorts respectively. We also observed serological evidence from N, S and RBD antibodies of breakthrough infection in 8/49 (16%) of Nigerian vaccinees over only 2 months, with neutralisation profiles suggesting delta variant infection consistent with the sampling period when this variant was known to dominate. Importantly, neutralising antibodies waned at 3 months after second dose vs 1 month post second-dose 1695 (4.3)] vs 2579 (4.2) in the Nigerian population who were N negative throughout. IgG anti-N was also observed to wane below cut-off in a total 19/94 (20%) of subjects highlighting the need for a combination of additional markers to characterise previous infection. We conclude that AZD1222 is immunogenic in two independent real world West African cohorts with high background seroprevalence and incidence of breakthrough infection in 2021. Waning titres at 6 months post second dose indicates the need for booster dosing after AZD1222 in the African setting despite hybrid immunity from previous infection.